200 related articles for article (PubMed ID: 35029286)
21. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
22. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
23. Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer.
Dmello RS; Palmieri M; Thilakasiri PS; Doughty L; Nero TL; Poh AR; To SQ; Lee EF; Douglas Fairlie W; Mielke L; Parker MW; Poon IKH; Batlle E; Ernst M; Chand AL
Cell Death Dis; 2024 Apr; 15(4):255. PubMed ID: 38600086
[TBL] [Abstract][Full Text] [Related]
24. The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
Romero IL; Lee W; Mitra AK; Gordon IO; Zhao Y; Leonhardt P; Penicka CV; Mui KL; Krausz TN; Greene GL; Lengyel E
Gynecol Oncol; 2012 Jan; 124(1):134-41. PubMed ID: 21996264
[TBL] [Abstract][Full Text] [Related]
25. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
Kandala PK; Srivastava SK
BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
[TBL] [Abstract][Full Text] [Related]
26. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
Yang X; Gao Y; Liu Q; Wan L; Liu H; Bian W; Du Y; Huang C
Oncol Rep; 2021 Feb; 45(2):459-468. PubMed ID: 33416163
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice.
Shi W; Ma H; Liu T; Yan D; Luo P; Zhai M; Tao J; Huo S; Guo J; Li C; Lin J; Zhang C; Li S; Lv J; Lin L
J Cell Mol Med; 2020 Apr; 24(8):4748-4761. PubMed ID: 32164044
[TBL] [Abstract][Full Text] [Related]
29. Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.
Yang J; Xing H; Lu D; Wang J; Li B; Tang J; Gu F; Hong L
J Cell Mol Med; 2019 Jun; 23(6):4005-4018. PubMed ID: 30993885
[TBL] [Abstract][Full Text] [Related]
30. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
31. Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells.
Wu X; Xiao H; Wang R; Liu L; Li C; Lin J
Curr Cancer Drug Targets; 2016; 16(7):631-8. PubMed ID: 26373715
[TBL] [Abstract][Full Text] [Related]
32. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
[TBL] [Abstract][Full Text] [Related]
33. Bazedoxifene Suppresses the Growth of Osteosarcoma Cells by Inhibiting IL-6 and IL-11/GP130 Signaling Pathway.
Wu X; Cao Y; Xiao H; Feng J; Lin J
J Pediatr Hematol Oncol; 2024 Jan; 46(1):8-14. PubMed ID: 37962127
[TBL] [Abstract][Full Text] [Related]
34. Tanshinone IIA Inhibits Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Modulation of STAT3-CCL2 Signaling.
Huang SY; Chang SF; Liao KF; Chiu SC
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28757590
[TBL] [Abstract][Full Text] [Related]
35. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
36. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
Zhang R; Yang X; Roque DM; Li C; Lin J
PLoS One; 2021; 16(4):e0240145. PubMed ID: 33909625
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
38. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
39. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway.
Chen X; Yang W; Deng X; Ye S; Xiao W
Mol Vis; 2020; 26():517-529. PubMed ID: 32818015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]